Dermatology

Standard of Care: Treatments and Monitoring

At a Glance

Treatment for Lichen Planopilaris and Frontal Fibrosing Alopecia focuses on calming inflammation and stabilizing further scarring hair loss, not usually regrowing hair already lost. Regular photos, scalp checks, and medication-specific safety tests help detect silent activity and guide care.

Treating Lichen Planopilaris (LPP) and Frontal Fibrosing Alopecia (FFA) is a marathon, not a sprint. Because these are scarring conditions, the central goal of any treatment is to control inflammation to protect the hair you still have ^[1].

It is vital to understand that success is defined by stabilization—stopping the patches or hairline from growing further—rather than hair regrowth. While some patients experience minor regrowth in partially damaged areas, follicles that have been fully replaced by scar tissue cannot produce new hair ^[1]^[2]. There is no universally effective regimen or broadly approved treatment for LPP/FFA; treatment selection is highly individualized.

First-Line Treatments: Targeted Relief

For most patients, treatment begins with targeted therapies applied directly to the active areas of the scalp. These are often used for mild-to-moderate disease or as a starting point.

Topical Treatments: High-potency corticosteroids (like clobetasol) or topical calcineurin inhibitors are used to calm surface inflammation and reduce symptoms like itching and burning ^[3]^[4].
Intralesional Injections: Your doctor may inject a steroid (triamcinolone) directly into the “active edge” of a hair loss patch. This delivers the medication to the upper part of the hair follicle (the infundibulum and isthmus) where the immune attack is occurring. Warning: Injection dose and spacing must be carefully managed by your clinician, as they carry risks of scalp atrophy (thinning) and hypopigmentation (color loss) ^[3]^[5].

Systemic Options: Medications for Progressive Disease

If your hair loss is moving quickly, covers a large area, or doesn’t respond to topicals, your doctor may recommend systemic (oral) medications. These work from the inside out to suppress the immune system. Many of these are used “off-label,” and evidence often comes from small observational studies rather than large clinical trials.

Hydroxychloroquine (HCQ)

HCQ is one of the most common systemic treatments for LPP. It helps decrease disease activity, with many patients seeing maximum benefit after about 12 months of therapy ^[6]^[7].

Monitoring & Safety: The most significant risk is retinal toxicity (permanent damage to the back of the eye). Dosing should not exceed 5 mg per kg of your actual body weight. You must have a baseline eye exam before starting, followed by screenings based on current ophthalmology guidance and your specific risk factors (such as kidney disease, tamoxifen use, or dose/duration) ^[8]^[9].

Immunosuppressants

If HCQ is not enough, other immunosuppressants may be used. While some small, heterogeneous retrospective studies have reported high response rates (e.g., 79% to 85% for methotrexate, or up to 100% for cyclosporine in small cohorts), these numbers depend heavily on how the study defined “response” and should not be viewed as a guaranteed outcome ^[10]^[11].

Methotrexate: Requires regular monitoring of blood counts and liver function. Strict pregnancy precautions are required.
Cyclosporine: Requires careful monitoring of blood pressure and kidney function. Due to higher side effect risks, it is often used for shorter periods.
Mycophenolate Mofetil (MMF): Requires monitoring for infection risk, blood counts, and kidney function.

Special Considerations for FFA

For patients with Frontal Fibrosing Alopecia, current expert consensus often considers adding medications called 5-alpha-reductase inhibitors, such as dutasteride or finasteride ^[12]. Note that these do not replace anti-inflammatory treatments when active inflammation is present.

Effectiveness: Observational studies suggest these medications can help stabilize the hairline in a significant portion of patients (e.g., 62% to 88% depending on the dose) ^[13]^[14].
Monitoring & Safety: These drugs can cause birth defects and must be handled with strict pregnancy precautions. They also have potential sexual and mood side effects ^[15].

The Risk of Stopping Treatment

Never start, stop, or change the dose of any systemic medication without your prescriber’s specific plan.
Abruptly stopping immunosuppressants can be unsafe depending on the drug. Furthermore, LPP can be “clinically silent”—the immune system can continue to attack follicles even if you don’t feel symptoms ^[16]^[17]. Approximately 27% to 29% of patients experience a “flare” or relapse of active hair loss after systemic therapy is withdrawn ^[18]^[19].

Monitoring Your Progress

Because you cannot always trust how your scalp feels, your care team should use objective tools to track your progress:

Standardized Photography: Photos taken periodically to catch small changes in the hairline or patches ^[1].
Clinical Scores: Tools like the LPPAI (LPP Activity Index) or FFASS track symptoms, redness, and scaling over time ^[20]^[21].
Trichoscopy: Checking the follicles for active “tubular scales” that signal inflammation is still present ^[7].

Common questions in this guide

What is the main goal of treatment for LPP or FFA?

The main goal is to calm inflammation and stop further spread of scarring hair loss. Treatment usually aims for stabilization rather than regrowth, because a follicle replaced by scar tissue cannot produce new hair. Some partially damaged areas may show limited regrowth.

When might I need oral medicine for LPP?

A dermatologist may consider oral treatment when hair loss is progressing quickly, covers a larger area, or does not improve with topical treatment. Options can include hydroxychloroquine or other immune-suppressing medicines, and many are used off-label. The choice depends on your disease activity, health history, pregnancy plans, and medication risks.

What eye monitoring is needed if I take hydroxychloroquine for LPP?

Hydroxychloroquine should be dosed no higher than 5 mg per kilogram of actual body weight to reduce the risk of retinal toxicity. A baseline eye exam is needed before treatment, followed by screening based on eye-care guidance and risk factors such as kidney disease, tamoxifen use, dose, and treatment duration.

What tests are needed for LPP medicines such as methotrexate or cyclosporine?

Methotrexate requires regular blood-count and liver-function checks. Cyclosporine requires blood-pressure and kidney monitoring, while mycophenolate requires checks for infection risk, blood counts, and kidney function. Your prescriber should give you a schedule based on the medicine and your health.

Can dutasteride or finasteride help with frontal fibrosing alopecia?

These medicines may help stabilize the hairline in some people with FFA, but they do not replace anti-inflammatory treatment when inflammation is active. They require strict pregnancy precautions and may cause sexual or mood-related side effects. Discuss whether the potential benefits and risks fit your situation.

Can LPP remain active even when my scalp no longer itches?

Yes. LPP can continue damaging follicles without obvious symptoms, so improvement in itching alone does not prove that disease activity has stopped. Doctors may use serial photographs, clinical activity scores, and trichoscopy to look for ongoing inflammation; do not stop systemic medicine without a prescriber's plan.

Key takeaways

The main treatment goal in LPP and FFA is to control inflammation and stabilize further scarring hair loss; fully scarred follicles generally cannot regrow hair.
Topical corticosteroids, topical calcineurin inhibitors, and carefully administered steroid injections may be used for localized or milder active disease.
Progressive disease may require oral medicines such as hydroxychloroquine or immunosuppressants, each with specific eye, blood, kidney, liver, or blood-pressure monitoring.
Dutasteride or finasteride may help stabilize the FFA hairline but do not replace anti-inflammatory treatment and require strict pregnancy precautions.
Standardized photographs, activity scores, and trichoscopy can reveal ongoing or silent inflammation, so medication changes should follow a clinician's plan.

References (21)

1
Management of classic lichen planopilaris: The EADV task force on hair diseases position statement.
Seyed Jafari SM, Starace M, Katoulis A, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV 2026; (40(8)):1306-1317 doi:10.1111/jdv.70379.
PMID: 41848299
2
5-alpha-reductase inhibitor treatment for frontal fibrosing alopecia: an evidence-based treatment update.
Murad A, Bergfeld W
Journal of the European Academy of Dermatology and Venereology : JEADV 2018; (32(8)):1385-1390 doi:10.1111/jdv.14930.
PMID: 29524253
3
Lichen Planopilaris and Low-Level Light Therapy: Four Case Reports and Review of the Literature About Low-Level Light Therapy and Lichenoid Dermatosis.
Randolph MJ, Salhi WA, Tosti A
Dermatology and therapy 2020; (10(2)):311-319 doi:10.1007/s13555-020-00359-x.
PMID: 32060796
4
Prevalence and Treatment Patterns in Patients With Lichen Planopilaris.
Pelet Del Toro N, Strunk A, Garg A, Han G
JAMA dermatology 2024; (160(8)):865-868 doi:10.1001/jamadermatol.2024.1445.
PMID: 38865116
5
Lichen planopilaris and frontal fibrosing alopecia: review and update of diagnostic and therapeutic features.
Fechine COC, Valente NYS, Romiti R
Anais brasileiros de dermatologia 2022; (97(3)):348-357 doi:10.1016/j.abd.2021.08.008.
PMID: 35379508
6
The efficacy of antimalarial drugs in the therapy of selected forms of cicatricial alopecia.
Zbiciak-Nylec MA, Brzezińska-Wcisło L, Salwowska N
Postepy dermatologii i alergologii 2021; (38(2)):302-309 doi:10.5114/ada.2021.106208.
PMID: 34408598
7
Clinical effectiveness of finasteride versus hydroxychloroquine in the treatment of frontal fibrosing alopecia: A randomized controlled trial.
Saber M, Farokhshahi M, Fatemi Naeini F, et al.
Journal of cosmetic dermatology 2024; (23(2)):576-584 doi:10.1111/jocd.15993.
PMID: 37691183
8
Hydroxychloroquine in dermatology: New perspectives on an old drug.
Chew CY, Mar A, Nikpour M, Saracino AM
The Australasian journal of dermatology 2020; (61(2)):e150-e157 doi:10.1111/ajd.13168.
PMID: 31612996
9
Target in Sight: A Comprehensive Review of Hydroxychloroquine-Induced Bull's Eye Maculopathy.
Snow Z, Seely K, Barrett S, et al.
Current ophthalmology reports 2024; (12(3)):38-48 doi:10.1007/s40135-024-00321-6.
PMID: 39371107
10
Systemic Treatments for Lichen Planopilaris and Frontal Fibrosing Alopecia: A Retrospective Study of 315 Patients.
Willaert M, Van Dongen T, Dikrama P, et al.
Acta dermato-venereologica 2025; (105()):adv42465 doi:10.2340/actadv.v105.42465.
PMID: 40293264
11
Lichen planopilaris: retrospective study on the characteristics and treatment of 291 patients.
Babahosseini H, Tavakolpour S, Mahmoudi H, et al.
The Journal of dermatological treatment 2019; (30(6)):598-604 doi:10.1080/09546634.2018.1542480.
PMID: 30411987
12
Consensus Document on the Clinical Management of Frontal Fibrosing Alopecia: Recommendations From Spanish Working Group on Trichology and Onychology of the AEDV.
Saceda-Corralo D, Combalia A, Fernandez-Crehuet P, et al.
Actas dermo-sifiliograficas 2025; (117(1)):104486 doi:10.1016/j.ad.2025.104486.
PMID: 41344613
13
Effectiveness of dutasteride in a large series of patients with frontal fibrosing alopecia in real clinical practice.
Pindado-Ortega C, Saceda-Corralo D, Moreno-Arrones ÓM, et al.
Journal of the American Academy of Dermatology 2021; (84(5)):1285-1294 doi:10.1016/j.jaad.2020.09.093.
PMID: 33038469
14
Dutasteride in the treatment of frontal fibrosing alopecia: Systematic review and meta-analysis.
Seo HM, Oh SU, Kim S, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV 2024; (38(8)):1514-1521 doi:10.1111/jdv.19802.
PMID: 38357767
15
The efficacy and use of finasteride in women: a systematic review.
Hu AC, Chapman LW, Mesinkovska NA
International journal of dermatology 2019; (58(7)):759-776 doi:10.1111/ijd.14370.
PMID: 30604525
16
Diffuse Lichen Planopilaris Masquerading as Diffuse Alopecia Areata.
Yoo LJH, Meah N, Wall D, McDonald I
Case reports in dermatology 2024; (16(1)):83-87 doi:10.1159/000538064.
PMID: 38529513
17
"Normal-appearing" scalp areas are also affected in lichen planopilaris and frontal fibrosing alopecia: An observational histopathologic study of 40 patients.
Doche I, Romiti R, Hordinsky MK, Valente NS
Experimental dermatology 2020; (29(3)):278-281 doi:10.1111/exd.13834.
PMID: 30403306
18
Clinical Insights and Prognostic Factors in Frontal Fibrosing Alopecia and Lichen Planopilaris: A Retrospective Cohort Study.
Lyakhovitsky A, Zilbermintz T, Jaworowski B, et al.
Dermatology (Basel, Switzerland) 2026; 1-11 doi:10.1159/000553195.
PMID: 42334990
19
Treatment of Lichen Planopilaris and Frontal Fibrosing Alopecia: A Retrospective, Real-Life Analysis in a Tertiary Center in Germany.
Stege H, Haist M, Schultheis M, et al.
Journal of clinical medicine 2024; (13(16)) doi:10.3390/jcm13164947.
PMID: 39201087
20
Comparative Efficacy Study Combination of Oral Methotrexate and Prednisolone versus Oral Methotrexate in Patients with Lichen Planopilaris.
Fatemi F, Esfahanian F, Asilian A, et al.
Dermatology research and practice 2022; (2022()):3792489 doi:10.1155/2022/3792489.
PMID: 36254319
21
Development and validation of the Frontal Fibrosing Alopecia Severity Score.
Saceda-Corralo D, Moreno-Arrones ÓM, Fonda-Pascual P, et al.
Journal of the American Academy of Dermatology 2018; (78(3)):522-529 doi:10.1016/j.jaad.2017.09.034.
PMID: 28947289

This page is for informational purposes only and does not constitute medical advice. A dermatologist or other qualified clinician should tailor LPP or FFA medications, pregnancy precautions, eye exams, laboratory tests, and follow-up to your situation.

Guide Contents